Claims are open. A claim must be submitted online by 11:59 p.m. ET on January 19, 2027, or mailed with a
postmark no later than that date. Judge Indira Talwani of the U.S. District Court for the District of
Massachusetts granted preliminary approval on October 27, 2026, and the settlement fairness hearing is set for
March 5, 2027 at 10:00 a.m. ET. Nothing is paid unless the court grants final approval, and no payment date has
been announced.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Status
Claims Open
Claim Deadline
January 19, 2027
Estimated Payout
About $1.12 a share
Before fees · July 22 – Nov. 5, 2020 buys · about $0.19 a share for earlier buys
Proof Required
Yes
Broker confirmations or account statements for every listed trade
The claim period opened after the court preliminarily approved the settlement on October 27, 2026. Strategic
Claims Services, the court-appointed claims administrator, is sending postcard and email notices and has posted
the notice, claim form and settlement papers on its case page.
The case is Shash v. Biogen Inc., et al., No. 1:21-cv-10479-IT. It was first filed in November 2020 in
federal court in California and moved to Massachusetts in 2021. Investors allege that Biogen and two former
executives, former CEO Michel Vounatsos and former research head Alfred W. Sandrock, Jr., violated the federal
securities laws by making false and misleading statements to investors. The settlement papers tie the case to
Biogen's Alzheimer's drug aducanumab, which was then before the FDA, and to the stock's moves around a
November 2020 FDA advisory committee meeting. Defendants deny all of the allegations and any wrongdoing, and the
settlement is not an admission of liability.
The court dismissed the complaint in September 2022. In October 2023 the U.S. Court of Appeals for the First
Circuit affirmed the dismissal except for claims based on one statement, which kept alive only claims for stock
bought from July 22, 2020 on. The parties accepted a mediator's proposal on August 3, 2026 and signed the
Stipulation of Settlement on October 6, 2026.
The settlement class is all persons and entities that purchased or otherwise acquired Biogen common stock
(Nasdaq: BIIB, CUSIP 09062X103) between October 22, 2019 and November 5, 2020, inclusive. Only publicly traded
common stock counts. Shares received by gift or inheritance are not treated as purchases, and options and
covering purchases on short sales are not eligible.
The defendants, their immediate families, Biogen's officers and directors during the class period and their
families, and entities they control are excluded, along with anyone who opts out.
The $25 million fund is split into two pools, each divided pro rata among the claimants who qualify for it:
- $20 million for shares bought from July 22, 2020 through November 5, 2020, the period still active in the case. Plaintiffs' damages consultant estimates an average recovery of about $1.12 a share before fees and expenses, or about $0.66 after them.
- $5 million for shares bought from October 22, 2019 through July 21, 2020, the period whose claims were dismissed. The estimate is about $0.19 a share before fees and expenses, or about $0.11 after them.
Those figures are averages from the notice, not a prediction for any one investor. Each claim is scored by a
recognized loss per share. Shares sold on or before November 5, 2020 get nothing. For shares held through
February 2, 2021, the recognized loss is the lesser of $25.21 a share or the purchase price minus $255.32, the
stock's 90-day average closing price after the disclosure. For shares sold between November 6, 2020 and
February 2, 2021, the loss is the lesser of $25.21 or the purchase price minus the average closing price through
the sale date. Purchases and sales are matched first-in, first-out.
A claimant with an overall trading gain, or who broke even, in Biogen stock during the class period receives
nothing, and no payment under $10 is issued. Lead Counsel, The Rosen Law Firm, will ask for attorneys' fees of
up to one-third of the fund ($8,333,333.33) plus up to $1.9 million in litigation expenses and up to $45,000 for
the plaintiffs' own costs. All of it comes out of the fund, along with administration costs. Money left after
redistribution goes to the Massachusetts Legal Assistance Corporation.
Brokerage records are required. The online claim form has an upload step, and the claim form asks for broker
confirmation slips or account statements documenting every purchase and sale listed, plus holdings at the close
of trading on October 21, 2019 and February 2, 2021. The transaction schedule must balance: beginning holdings
plus purchases, minus sales and ending holdings, must equal zero. Claims filed without supporting documents can
be rejected.
No notice ID or PIN is needed to file. Brokers, nominees and institutions filing for many accounts must use the
administrator's electronic filing template instead of the online form.
Online claims are due by 11:59 p.m. ET on January 19, 2027; mailed claims must be postmarked by January 19,
2027. Other dates set by the court's order and the notice:
- January 19, 2027 — exclusion requests must be received by the administrator
- February 12, 2027 — objections must be filed with the court and received by counsel (21 days before the hearing)
- March 5, 2027 at 10:00 a.m. ET — settlement fairness hearing, Courtroom 9, U.S. District Court in Boston
The administrator's case page lists January 19, 2027 for objections; the court-approved notice and the
preliminary approval order set the objection deadline at 21 days before the hearing, which is February 12, 2027.
Claims are filed through the
online claim form
on the Strategic Claims Services case page. The form runs in six steps: instructions, claimant information, a
schedule of Biogen transactions, document upload and a signed certification. A confirmation email with a Form
ID follows submission. A paper claim form is attached to the long-form notice for those who prefer to mail it.
Lead Counsel must file its papers supporting the settlement, the plan of allocation and the fee request at least
35 days before the March 5, 2027 hearing. At the hearing, the court will decide whether to grant final approval,
approve the plan of allocation and rule on fees. The hearing can be moved or held remotely; any change is posted
on the administrator's case page.
If the settlement is approved and becomes final, the administrator processes all claims and the court must
approve the distribution before checks go out. No distribution date has been announced.
Why do purchases before July 22, 2020 get less?
In 2022 the court dismissed the complaint, and in 2023 the First Circuit revived only the claims based on a single statement. That left only purchases from July 22, 2020 through November 5, 2020 actively in the case. The plan of allocation reflects that difference: $20 million is set aside for those purchases and $5 million for the earlier, dismissed period, with each pool divided pro rata among the claimants in it.
Does someone who sold before November 6, 2020 get anything?
No. Under the plan of allocation, shares bought in the class period and sold on or before November 5, 2020 have a recognized loss of zero. Only shares still held after that date, or sold between November 6, 2020 and February 2, 2021, can produce a recognized loss.
Is this the same as the $18.9 million Biogen settlement?
No. That is a separate securities case covering Biogen stock bought in June and July 2021, after the FDA approved aducanumab. This $25 million settlement covers purchases from October 22, 2019 through November 5, 2020. Each has its own claim form and deadline.
Are small claims paid?
Not if the calculated payment is under $10. The plan of allocation says no distribution will be made on a claim whose payment would be less than $10.00. A claimant who had an overall trading gain or broke even in Biogen stock during the class period also receives nothing.
For more class actions keep scrolling below.
Settlement Amount
$25,000,000
$20M for July 22 – Nov. 5, 2020 buys · $5M for Oct. 22, 2019 – July 21, 2020 buys
Case Title
Shash v. Biogen Inc., et al.
Case Number
1:21-cv-10479-IT
Court
U.S. District Court, District of Massachusetts
Final Approval Hearing
March 5, 2027 at 10:00 AM ET
Courtroom 9, Boston · Judge Indira Talwani · may be held remotely
Administrator
Strategic Claims Services